Cochlear invests €13 million in Nyxoah

Company News

by Anna Napoli

Hearing device company, Cochlear, (ASX:COH) has invested €13 million in Nyxoah (SA)

Nyxoah is a medical device company focused on the development and commercialisation of a best-in-class hypoglossal therapy for the treatment of obstructive sleep Apnea.

Cochlear says it actively monitors the market for novel technologies that over the long term may leverage or enhance its core technology

The investment comes on the back of a new agreement with audio solutions company, GN last week.

Shares in Cochlear (ASX:COH) are down 3.13 per cent to $169.96.



 

Anna Napoli

Finance News Network
Anna joined FNN February 2018 and also works with Channel 7 as a freelance producer. Anna has also worked as a lawyer and lecturer. She has also presented news updates for interstate news with Southern Cross Austereo.